OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Buske on the Results of the iNNOVATE Trial in Waldenström Macroglobulinemia

December 7th 2020

Christian Buske, MD, discusses the results of the iNNOVATE trial in Waldenström macroglobulinemia.

Dr. Mesa on the Anticipated Utility of Momelotinib in Myelofibrosis

December 7th 2020

Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.

Dr. Jain on the Rationale to Evaluate Ibrutinib/Rituximab in MCL

December 7th 2020

Preetesh Jain, MD, PhD, discusses the rationale to evaluate ibrutinib in combination with rituximab in mantle cell lymphoma.

Dr. Voorhees on Updated Results of the GRIFFIN Trial in Multiple Myeloma

December 7th 2020

Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute, of Atrium Health, discusses updated results of the GRIFFIN trial in multiple myeloma.

Dr. Cutler on the Results of the ROCKstar Study in cGVHD

December 6th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses the results of the ROCKstar study in chronic graft-versus-host disease.

Dr. Vasileiou on the Potential Role of ALVR109 for the Treatment of COVID-19

December 6th 2020

Spyridoula Vasileiou, PhD, discusses the potential role of ALVR109, a SARS-CoV-2 virus–specific T-cell therapy, for the treatment of coronavirus disease 2019.

Dr. Verstovsek on the Results of the PV-AIM trial in Polycythemia Vera

December 5th 2020

Srdan Verstovsek, MD, PhD, discusses findings from the PV-AIM trial in polycythemia vera.

Dr. Wierda on the Results of the CAPTIVATE Trial in CLL and SLL

December 5th 2020

William G. Wierda, MD, PhD, discusses results from the CAPTIVATE trial in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. El Chaer on the Role of Next-Generation Sequencing in MPNs

December 4th 2020

Firas El Chaer, MD, discusses the role of next-generation sequencing (NGS) in myeloproliferative neoplasms.

Dr. Seymour on Investigational BTK Inhibitors in CLL

December 4th 2020

Erlene Seymour, MD, discusses investigational BTK inhibitors in chronic lymphocytic leukemia.

Dr. Ruan on Future Research With CAR T-Cell Therapy in MCL

December 4th 2020

Jia Ruan, MD, PhD, discusses future research with CAR T-cell therapy in mantle cell lymphoma.

Dr. Shah on Dosing Tandem Receptor CAR T-Cell Therapy in B-Cell Malignancies

December 3rd 2020

Nirav N. Shah, MD, associate professor, Medical College of Wisconsin, discusses the dosing of tandem receptor CAR T-cell therapy in B-cell malignancies.

Dr. Bose on Risk Factors of Essential Thrombocythemia

December 3rd 2020

Prithviraj Bose, MD, discusses risk factors associated with essential thrombocythemia.

Dr. Patt on the Role of Sacituzumab Govitecan in TNBC

December 3rd 2020

Debra Patt, MD, PhD, MBA, breast medical oncologist, vice president of Texas Oncology, highlights the role of sacituzumab govitecan-hziy in triple-negative breast cancer.

Dr. Brody on the Expanding Role of Venetoclax in MCL

December 3rd 2020

Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.

Dr. Rapisuwon on the Frontline Treatment of Acral and Mucosal Melanoma

December 3rd 2020

Suthee Rapisuwon, MD, discusses the frontline treatment of acral and mucosal melanoma.

Dr. Winter on Emerging Agents in CLL

December 3rd 2020

Allison Winter, MD, discusses emerging agents in chronic lymphocytic leukemia.

Dr. Petrylak on the Role of Docetaxel in mHSPC

December 2nd 2020

Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Dr. Sehgal on Key Targetable Alterations in AML

December 2nd 2020

Alison R. Sehgal, MD, discusses key targetable alterations in acute myeloid leukemia.

Dr. Ayers on the Evolving Treatment Landscape in CLL

December 2nd 2020

Emily C. Ayers, MD, hematologist/oncologist, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.